To include your compound in the COVID-19 Resource Center, submit it here.

Versartis falls on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) plummeted $18.20 (84%) to $3.40 in after-hours trading Thursday after reporting that somavaratan (VRS-317) missed the primary endpoint of

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE